Biogen asked Charles River Associates to investigate the different factors that create barriers to patient access to multiple sclerosis (MS) treatments in Europe and to develop a set of credible recommendations to health policymakers at national and EU levels as well as national payers and clinicians, regarding practical measures that could improve access to treatment for MS patients. This research builds on a study conducted by CRA in 2014, which revealed that inequities in access to Disease Modifying Drugs (DMDs) used to treat MS still exist across Europe, with significant variations by country. To read the report, click the link below.
GLP-1 access is shifting – Are stakeholders ready?
CRA’s Becky Davis examines how these dramatic price reductions, combined with Direct-to-Patient distribution models, may be accelerating employer migration...